Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN reported provisional separate financial results for FY2025, recording revenue of KRW 202.12B (+117.4% YoY) and operating profit of KRW 114.80B (+274.8% YoY).
📊 [Key Disclosure Details & Major Figures Summary]
- Reporting Period: January 01, 2025 – December 31, 2025 (FY2025 Annual Provisional Results)
- Accounting Standard: K-IFRS Separate Financial Statements
- Revenue:
- FY2025 Result: KRW 202,116M (Approx. KRW 202.12B)
- YoY Change (vs. FY2024): +117.4% (FY2024: KRW 92,969M)
- Operating Profit:
- FY2025 Result: KRW 114,797M (Approx. KRW 114.80B)
- YoY Change (vs. FY2024): +274.8% (FY2024: KRW 30,630M)
- Profit Before Income Tax & Net Profit: To be re-disclosed following the completion of annual closing
- Precautionary Note:
- Figures represent provisional separate internal closing data prior to external audit and are subject to change based on final audit results.
- Profit before income tax, net profit, and final adjustments will be disclosed in subsequent filings upon completion of financial statements closing.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Official Audit Report and Annual Report Filings Post-Provisional Announcement
This disclosure provides preliminary separate annual sales figures for FY2025 prior to external audit completion. Reviewing the upcoming official Audit Report and Annual Report containing complete figures—including pre-tax profit and net income—is essential because it allows investors to confirm any variances between provisional figures and audited final results. Detailed confirmed figures and disclosures can be cross-checked in subsequent Audit Reports and periodic filings (Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
